Iaea tecdoc 1340
Porter, Cellular Uptake Mechanisms of Functionalised Multi-Walled Carbon Nanotubes by 3d Electron Tomography Imaging, Nanoscale, vol. Pascu, Encapsulation of Cadmium Selenide Nanocrystals in Biocompatible Nanotubes: DFT Calculations, X-Ray Diffraction Investigations, and Confocal Fluorescence Imaging, vol. Pastorin et al., Clinical Applications of Carbon Nanomaterials in Diagnostics and Therapy, Adv. Wilson, Toward Carbon Nanotube-Based Imaging Agents for the Clinic, Biomaterials, vol. Davis, Can Carbon Nanotubes Deliver on Their Promise in Biology? Harnessing Unique Properties for Unparalleled Applications, ACS Central Sci, vol. Dai, Carbon Nanomaterials for Biological Imaging and Nanomedicinal Therapy, Chem. Kim, Immunomodulating Nanomedicine for Cancer Therapy, Nano Lett, vol. Caruso, Bridging Bio-Nano Science and Cancer Nanomedicine, ACS Nano, vol. , Nanomedicines for Pediatric Cancers, ACS, vol. , Simultaneous Stealth Surface and Enhanced Cellular Uptake, ACS Nano, vol. Ji, Rational Design of Cancer Nanomedicine for Rao et al., Nanotechnology Strategies to Advance Outcomes in Clinical Cancer Care, ACS, vol. Wenzel TJ, Zomlefer K, Rapkin SA, Keith RH (1995) Lanthanide luminescence detection of bleomycins and nalidixic acid.C. Umezawa HT, Takeuchi S, Hori T (1972) Studies on the mechanisms of anti-tumor effects of bleomycin on squamous cell carcinoma. (1982) Retrosynthetic manipulation of bleomycins.
#Iaea tecdoc 1340 Pc#
Sullivan JC, Friedman AM, Rayudu GVS, Fordham EW,Ramachandran PC (1075) Tumor localization studies with radioactive lanthanide and actinide complexes. Stern PH, Halpern SE, Hagan PL, Howell SB, Dabbs JE, Gordon RM (1981) Cytotoxic activity, tumor accumulationand tissue distribution of ruthenium-103-labeled-bleomycin.
Royal Pharmaceutical Society, London, pp 546–547ġ7. Reynolds JE, Martindale I (ed) (1996) The extra pharmacopoeia, 31st ed. Michael RB, Andrews PM, Rosario AV, Goldenberg DM, Mattes MJ (2005) 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. Melnyk DL, Horwitz SB, Peisach T (1987) The oxidation-reduction potential of copper-bleomycin. Potentiometric, fluorescence and proton NMR studies. Lenkinski RE, Peerce, BE, Pillai MRI, Glickson JD (1980) Calcium(II) and the trivalent lanthanide ion complexes of the bleomycin antibiotics. (1999) 111In-labelled bleomycin complex for the differentiation of high- and low-grade gliomas. Korppi-Tommola T, Huhmar H, Aronen HJ et al. (2009) Preparation and biological evaluation of bleomycin complex as a possible PET radiopharmaceutical. (2006) (III)-Bleomycin for tumor imaging. Jalilian AR, Shirazi B, Aboudzadeh R et al. Jalilian AR, Rowshanfarzad P, Sabet M, Novinrooz A, Raisali G (2005) Preparation of Bleomycin complex as a possible PET radiopharmaceutical. Jalilian AR, Fateh B, Ghergherehchi M, Karimian A (2005) Development of bleomycin as a possible PET tracer. International Atomic Energy Agency, ViennaĨ.
#Iaea tecdoc 1340 manual#
IAEA (2003) Manual for reactor produced radioisotopes.IAEA-TECDOC-1340. Chakraborty S, Das T, Sarma HD, Venkatesh M, Banerjee S (2008) Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer. Chakraborty S, Das T, Banerjee S, Sarma HD, Venkatesh M (2006) Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints. (2008) 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis.
Brooks RC, Canochan P, Vollano JF, Powel NA, Zwiet J (1999) Metal complexes of bleomycin: evaluation of -Bleomycin for use in targeted radiotherapy. (2009) Peptide receptor therapies in neuroendocrine tumors. Bahrami-Samani A, Ghannadi-Maragheh M, Jalilian AR, Mazidi M (2010) Biological studies of samarium-153 bleomycin complex in human breast cancer murine xenografts for therapeutic applications.